| Medical and Health Sciences | 2021-2025 | 960 | US 336 | 99.77 |
| Obstetrics and Gynecology | Lifetime | 24 | US 6 | 99.81 |
| Reproductive Medicine | Lifetime | 76 | US 33 | 99.55 |
| Pediatrics, Perinatology and Child Health | Lifetime | 338 | US 160 | 99.01 |
| Internal Medicine | Lifetime | 473 | US 197 | 86.95 |
| Obstetrics and Gynecology | 2021-2025 | 25 | US 6 | 99.42 |
| Reproductive Medicine | 2021-2025 | 49 | US 12 | 98.76 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 265 | US 98 | 94.79 |
| Epidemiology | 2021-2025 | 557 | US 192 | 94.86 |
| Oncology | 2021-2025 | 404 | US 172 | 95.27 |
| Public, Environmental and Occupational Health | 2021-2025 | 632 | US 238 | 94.02 |
| Genetics | 2021-2025 | 786 | US 288 | 74.51 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 17 | US 9 | 99.75 |
| Uterine Myomas and Treatments | Lifetime | 13 | US 3 | 99.78 |
| Endometriosis Research and Treatment | Lifetime | 41 | US 14 | 99.55 |
| Ovarian cancer diagnosis and treatment | Lifetime | 62 | US 37 | 99.59 |
| Maternal and fetal healthcare | Lifetime | 32 | US 13 | 99.56 |
| Cervical Cancer and HPV Research | Lifetime | 77 | US 38 | 99.49 |
| COVID-19 and healthcare impacts | Lifetime | 131 | US 48 | 97.57 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 53 | US 24 | 99.12 |
| Colorectal and Anal Carcinomas | Lifetime | 130 | US 68 | 98.85 |
| Economic and Financial Impacts of Cancer | Lifetime | 100 | US 64 | 98.41 |
| Gynecological conditions and treatments | Lifetime | 80 | US 25 | 98.73 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 744 | US 368 | 98.54 |
| Maternal and Perinatal Health Interventions | Lifetime | 160 | US 61 | 98.80 |
| Ectopic Pregnancy Diagnosis and Management | Lifetime | 125 | US 52 | 98.17 |
| Pelvic and Acetabular Injuries | Lifetime | 422 | US 234 | 97.60 |
| Minimally Invasive Surgical Techniques | Lifetime | 120 | US 56 | 97.06 |
| Pregnancy and preeclampsia studies | Lifetime | 947 | US 337 | 97.22 |
| Multiple and Secondary Primary Cancers | Lifetime | 409 | US 177 | 96.06 |
| Cancer Risks and Factors | Lifetime | 794 | US 409 | 94.93 |
| Gestational Trophoblastic Disease Studies | Lifetime | 301 | US 129 | 91.14 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 31 | US 8 | 99.34 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 53 | US 14 | 99.04 |
| Uterine Myomas and Treatments | 2021-2025 | 32 | US 8 | 98.76 |
| Cervical Cancer and HPV Research | 2021-2025 | 58 | US 20 | 98.21 |
| Endometriosis Research and Treatment | 2021-2025 | 94 | US 13 | 97.58 |
| COVID-19 and healthcare impacts | 2021-2025 | 335 | US 113 | 94.41 |
| Global Cancer Incidence and Screening | 2021-2025 | 256 | US 104 | 95.34 |
| Maternal and fetal healthcare | 2021-2025 | 207 | US 85 | 93.68 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 289 | US 182 | 92.16 |
| Gynecological conditions and treatments | 2021-2025 | 104 | US 14 | 92.43 |
| Cancer Risks and Factors | 2021-2025 | 223 | US 87 | 90.37 |
| Maternal and Perinatal Health Interventions | 2021-2025 | 654 | US 208 | 87.46 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 328 | US 123 | 81.68 |
| Ectopic Pregnancy Diagnosis and Management | 2021-2025 | 249 | US 73 | 81.97 |
| Healthcare cost, quality, practices | 2021-2025 | 485 | US 206 | 80.04 |
| BRCA gene mutations in cancer | 2021-2025 | 986 | US 426 | 80.52 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 550 | US 132 | 79.53 |
| Medication Adherence and Compliance | 2021-2025 | 727 | US 247 | 72.91 |
| Pain Management and Opioid Use | 2021-2025 | 740 | US 382 | 72.88 |
| Menopause: Health Impacts and Treatments | 2021-2025 | 758 | US 244 | 52.80 |
| Gestational Trophoblastic Disease Studies | 2021-2025 | 787 | US 121 | 24.86 |
